Protara Therapeutics Employee Directory
Biotechnology ResearchNew York, United States51-200 Employees
Protara Therapeutics is a mid-sized biotechnology company focused on developing therapies for cancer and rare diseases. Its lead program, TARA-002, is a cell therapy in development for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride is an intravenous phospholipid substrate replacement under investigation for intestinal failure-associated liver disease. Headquartered in New York, New York, the company operates within the biotechnology research sector, pursuing treatments for patients with limited options. Its portfolio targets bladder cancer, lymphatic malformations, and liver disease related to parenteral nutrition. In early 2026, Protara reported updated interim 12-month data from the Phase 2 ADVANCED-2 trial of TARA-002 at the American Urological Association Annual Meeting.